WXIBF
WuXi Biologics (Cayman) Inc.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Strong buy
+64/100
Last price
6.77
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
6.77
Day high
6.45
Day low
6.45
Volume
4.00K
Market cap
$27.87B
P/E (TTM)
39.82
52W range
3.90 – 6.77
Trailing performance
Returnvs SPY
1W
0.00%
-1.9%
1M
+8.76%
+7.6%
3M
+47.17%
+42.7%
6M
+47.17%
+29.0%
YTD
+60.43%
+46.2%
1Y
+20.76%
+4.3%
3Y
+20.25%
-62.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on WXIBF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
415.35M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 11, 26 | Chen (Zhisheng) Chief Executive Officer |
CONVERSION | 1.20M | $7.52M | Direct |
| Sep 9, 26 | Chen (Zhisheng) Chief Executive Officer |
CONVERSION | 1.20M | $403.44K | Direct |
| Sep 9, 26 | Chen (Zhisheng) Chief Executive Officer |
OTHER | 1.80M | $11.26M | Direct |
| Sep 8, 26 | Chen (Zhisheng) Chief Executive Officer |
SELL | 3.20M | $20.15M | Direct |
| Sep 7, 26 | Chen (Zhisheng) Chief Executive Officer |
CONVERSION | 1.80M | $605.37K | Direct |
| Sep 7, 26 | Chen (Zhisheng) Chief Executive Officer |
OTHER | 2.40M | $15.47M | Direct |
| Sep 4, 26 | Chen (Zhisheng) Chief Executive Officer |
CONVERSION | 3.20M | $1.08M | Direct |
| Sep 4, 26 | Chen (Zhisheng) Chief Executive Officer |
OTHER | 1.50M | $9.40M | Direct |
| Sep 3, 26 | Chen (Zhisheng) Chief Executive Officer |
CONVERSION | 2.40M | $807.12K | Direct |
| Sep 2, 26 | Chen (Zhisheng) Chief Executive Officer |
CONVERSION | 1.50M | $504.30K | Direct |
| Aug 24, 26 | Chen (Zhisheng) Chief Executive Officer |
— | 104.50K | — | Direct |
| Aug 24, 26 | Gu (Xuejun Sherry) Chief Technology Officer |
— | 15.12K | — | Direct |
| Jun 16, 26 | Chen (Zhisheng) Chief Executive Officer |
— | 378.08K | — | Direct |
| Jun 10, 26 | Chen (Zhisheng) Chief Executive Officer |
— | 264.87K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Chen (Zhisheng) |
Chief Executive Officer | 49.19M | Conversion |
Gu (Xuejun Sherry) |
Chief Technology Officer | 1.37M | Conversion |
Li (Ge) |
Chairman of the Board | — | Sale |
Zhou (Weichang) |
Chief Technology Officer | 5.60M | Other |
Fundamentals
Market cap$27.87B
Enterprise value$26.90B
Revenue (TTM)$23.62B
Gross profit$11.21B
EBITDA$9.02B
Net income$5.01B
EPS (TTM)$0.17
Free cash flow$2.42B
Total cash$13.03B
Total debt$2.73B
Book value / share$1.69
Shares outstanding4.12B
Float3.71B
Short % of float—
Dividend yield0.00%
Beta (5Y)0.59
Valuation & profitability ratios
Trailing P/E39.82
Forward P/E—
PEG ratio0.71
Price / sales—
Price / book4.00
EV / revenue1.14
EV / EBITDA2.98
Gross margin47.47%
Operating margin31.63%
Profit margin21.20%
Return on equity11.38%
Return on assets7.60%
Debt / equity5.00
Current ratio3.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $21.79B | $18.68B | $17.03B | $15.27B | +16.7% |
| Operating revenue | $21.79B | $18.68B | $17.03B | $15.27B | +16.7% |
| Cost of revenue | $11.77B | $11.02B | $10.21B | $8.54B | +6.8% |
| Gross profit | $10.02B | $7.65B | $6.83B | $6.72B | +30.9% |
| Research & development | $853.37M | $766.44M | $785.82M | $682.82M | +11.3% |
| Selling, general & admin | $2.31B | $2.15B | $1.79B | $1.43B | +7.7% |
| Total operating expense | $2.96B | $2.68B | $2.38B | $1.93B | +10.6% |
| Operating income | $7.06B | $4.97B | $4.45B | $4.80B | +41.9% |
| Net interest income | $251.52M | $192.78M | $60.69M | $43.09M | +30.5% |
| Pre-tax income | $7.26B | $4.83B | $4.17B | $5.36B | +50.1% |
| Tax provision | $1.52B | $889.03M | $603.18M | $807.87M | +71.4% |
| Net income | $4.91B | $3.36B | $3.40B | $4.42B | +46.3% |
| Net income to common | $4.91B | $3.36B | $3.40B | $4.42B | +46.3% |
| Basic EPS | 1.22 | 0.82 | 0.82 | 1.06 | +48.8% |
| Diluted EPS | 1.16 | 0.78 | 0.77 | 1.01 | +48.7% |
| EBIT | $7.40B | $4.99B | $4.33B | $5.42B | +48.2% |
| EBITDA | $8.85B | $6.43B | $5.50B | $6.22B | +37.6% |
| Basic shares | 4.03B | 4.08B | 4.16B | 4.17B | -1.3% |
| Diluted shares | 4.18B | 4.23B | 4.35B | 4.38B | -1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $9.21B | $8.28B | $9.67B | $6.40B | +11.3% |
| Cash & short-term investments | $15.73B | $10.71B | $11.24B | $8.71B | +46.9% |
| Accounts receivable | $7.65B | $5.52B | $5.65B | $4.65B | +38.6% |
| Inventory | $1.38B | $1.52B | $1.77B | $2.28B | -9.2% |
| Total current assets | $28.14B | $23.57B | $21.20B | $18.47B | +19.4% |
| Property, plant & equipment | $29.75B | $28.44B | $29.94B | $25.92B | +4.6% |
| Goodwill & intangibles | $2.00B | $1.97B | $2.04B | $2.08B | +1.3% |
| Total assets | $63.70B | $56.98B | $56.58B | $49.56B | +11.8% |
| Total current liabilities | $8.31B | $8.62B | $7.64B | $9.32B | -3.6% |
| Current debt | $873.52M | $2.44B | $576.33M | $1.32B | -64.1% |
| Long-term debt | $169.38M | $200.90M | $1.57B | $1.46B | -15.7% |
| Total debt | $3.10B | $4.94B | $4.56B | $4.42B | -37.2% |
| Total liabilities | $10.66B | $11.50B | $12.56B | $13.35B | -7.3% |
| Retained earnings | $20.81B | $16.36B | $13.49B | $10.52B | +27.2% |
| Shareholder equity | $47.25B | $41.82B | $40.33B | $35.05B | +13.0% |
| Working capital | $19.83B | $14.95B | $13.56B | $9.15B | +32.6% |
| Net tangible assets | $45.25B | $39.85B | $38.29B | $32.97B | +13.6% |
| Shares issued | 4.13B | 4.11B | 4.26B | 4.23B | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $7.26B | $4.83B | $4.17B | $5.36B | +50.1% |
| Depreciation & amortisation | $1.45B | $1.44B | $1.17B | $800.67M | +0.8% |
| Stock-based compensation | $955.05M | $1.22B | $1.27B | $1.23B | -21.4% |
| Change in working capital | -$1.73B | -$800.50M | -$896.35M | -$974.47M | -116.2% |
| Operating cash flow | $6.34B | $5.22B | $4.67B | $5.54B | +21.5% |
| Capital expenditure | -$3.74B | -$3.93B | -$4.23B | -$5.87B | +4.9% |
| Investing cash flow | -$3.09B | -$3.94B | -$3.23B | -$5.91B | +21.7% |
| Share buybacks | -$1.58B | -$1.77B | -$916.92M | -$2.80B | +10.7% |
| Financing cash flow | -$2.16B | -$2.75B | $1.96B | -$2.59B | +21.3% |
| Free cash flow | $2.61B | $1.29B | $437.20M | -$326.72M | +102.3% |
| End cash position | $9.21B | $8.28B | $9.67B | $6.40B | +11.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $9.21B | $8.44B | +9.2% |
| Cash & short-term investments | $15.73B | $12.54B | +25.5% |
| Accounts receivable | $7.65B | $6.82B | +12.2% |
| Inventory | $1.38B | $1.66B | -16.5% |
| Total current assets | $28.14B | $24.45B | +15.1% |
| Property, plant & equipment | $29.75B | $30.18B | -1.4% |
| Goodwill & intangibles | $2.00B | $1.97B | +1.3% |
| Total assets | $63.70B | $60.44B | +5.4% |
| Total current liabilities | $8.31B | $8.49B | -2.1% |
| Current debt | $873.52M | $2.55B | -65.7% |
| Long-term debt | $169.38M | $185.14M | -8.5% |
| Total debt | $3.10B | $5.11B | -39.2% |
| Total liabilities | $10.66B | $11.37B | -6.3% |
| Retained earnings | $20.81B | $18.70B | +11.3% |
| Shareholder equity | $47.25B | $44.95B | +5.1% |
| Working capital | $19.83B | $15.96B | +24.2% |
| Net tangible assets | $45.25B | $42.98B | +5.3% |
| Shares issued | 4.13B | 4.08B | +1.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $25.70B | +18.0% |
| Next year | — | — | $30.73B | +19.6% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders10.12%
Held by institutions36.38%
Institutions holding379
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.62
+2.30% from price
SMA 20
6.34
+6.86% from price
SMA 50
5.91
+14.64% from price
SMA 100
5.13
+32.00% from price
SMA 200
4.85
+39.58% from price
EMA 12
6.58
+2.90% from price
EMA 26
6.33
+6.93% from price
EMA 50
5.96
+13.60% from price
RSI (14)
85.5
Overbought
MACD (12,26,9)
0.25
Hist 0.03
ATR (14)
0.05
0.80% of price
Realised vol 30D
38.9%
Annualised
Bollinger upper
7.06
20, 2σ
Bollinger lower
5.62
20, 2σ
50 / 200 cross
Golden
5.91 vs 4.85
Trend bias
Above 200
+39.58%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.08
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
38.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-30.4%
Peak to trough
Max drawdown 5Y
-91.5%
Peak to trough
ATR 14
0.05
0.80% of price
Beta (reported)
0.59
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split3:1
Split dateDec 10, 2020
Headlines
Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption
GlobeNewswire · 7d ago
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability
PR Newswire · 14d ago
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
PR Newswire · 22d ago
Big Pharma Is Pouring Billions Into China’s Biotechs
Barrons.com · 24d ago
WuXi Biologics Reports Strong Profitable Growth in H1 2026
PR Newswire · 44d ago
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
PR Newswire · 51d ago
Is WuXi Biologics (Cayman) (SEHK:2269) Still Below Fair Value On FTSE4Good Recognition?
Simply Wall St. · 68d ago
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
PR Newswire · 71d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.